Merck & Co. Inc.'s PD-1 inhibitor Keytruda has failed to show a survival benefit in the KEYNOTE-040 study of head and neck cancer, which was meant to confirm an accelerated approval, but the company does not foresee a labeling change.
Merck sais July 24 that median overall survival (OS) for Keytruda in the study of recurrent or metastatic head and...






